BCAN Think Tank session 1

Overview of risks for and causes of bladder cancer

Alexandre R. Zlotta, Samuel Monroe Cohen, Colin Dinney, Michael Droller, Theo H. van der Kwast, Bas W G van Rhijn, Bernard Bochner, Gilad Ameil, Michael A S Jewett

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

This article reviews the proceedings of the cause and risk session of the recently held BCAN Bladder Think Tank in 2009. Understanding associations between specific genetic changes and development of particular forms of bladder cancer, whether low-grade or more invasive forms, may justify screening programs for earlier detection. A fundamental epidemiological issue is causation. Associations are supported by high rates in industrialized regions and parallel associations with cigarette smoking. The evolution to molecular and integrative epidemiology incorporates molecular and cytogenetic markers in host and tumor tissue with classic epidemiology to develop risk assessment models to identify high-risk populations. Animal models can teach us something about human bladder cancer and address the issue of the differentiation between papillary low-grade and invasive high-grade tumors. After the diagnosis of a bladder tumor, pathological risk stratification becomes important but there are weaknesses in the current grading systems. Molecular grading may provide a new, simple, and highly reproducible tool to determine bladder cancer prognosis. Based on our current knowledge, including gaps in that knowledge, education is the immediate top-priority action item. The promotion of smoking cessation is also a high priority action. The symptoms of bladder cancer, particularly hematuria, must be emphasized to both the medical and lay. Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number3
DOIs
StatePublished - May 1 2010

Fingerprint

Urinary Bladder Neoplasms
Molecular Epidemiology
Hematuria
Smoking Cessation
Cytogenetics
Causality
Neoplasms
Epidemiology
Urinary Bladder
Animal Models
Smoking
Education
Costs and Cost Analysis
Population

Keywords

  • Bladder cancer
  • Cancer risk
  • Carcinogenesis

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Zlotta, A. R., Cohen, S. M., Dinney, C., Droller, M., van der Kwast, T. H., van Rhijn, B. W. G., ... Jewett, M. A. S. (2010). BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 28(3), 329-333. https://doi.org/10.1016/j.urolonc.2009.10.011

BCAN Think Tank session 1 : Overview of risks for and causes of bladder cancer. / Zlotta, Alexandre R.; Cohen, Samuel Monroe; Dinney, Colin; Droller, Michael; van der Kwast, Theo H.; van Rhijn, Bas W G; Bochner, Bernard; Ameil, Gilad; Jewett, Michael A S.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 3, 01.05.2010, p. 329-333.

Research output: Contribution to journalReview article

Zlotta, AR, Cohen, SM, Dinney, C, Droller, M, van der Kwast, TH, van Rhijn, BWG, Bochner, B, Ameil, G & Jewett, MAS 2010, 'BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer', Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 3, pp. 329-333. https://doi.org/10.1016/j.urolonc.2009.10.011
Zlotta, Alexandre R. ; Cohen, Samuel Monroe ; Dinney, Colin ; Droller, Michael ; van der Kwast, Theo H. ; van Rhijn, Bas W G ; Bochner, Bernard ; Ameil, Gilad ; Jewett, Michael A S. / BCAN Think Tank session 1 : Overview of risks for and causes of bladder cancer. In: Urologic Oncology: Seminars and Original Investigations. 2010 ; Vol. 28, No. 3. pp. 329-333.
@article{5ad7b61930b147d9b4d7300ab1f105ec,
title = "BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer",
abstract = "This article reviews the proceedings of the cause and risk session of the recently held BCAN Bladder Think Tank in 2009. Understanding associations between specific genetic changes and development of particular forms of bladder cancer, whether low-grade or more invasive forms, may justify screening programs for earlier detection. A fundamental epidemiological issue is causation. Associations are supported by high rates in industrialized regions and parallel associations with cigarette smoking. The evolution to molecular and integrative epidemiology incorporates molecular and cytogenetic markers in host and tumor tissue with classic epidemiology to develop risk assessment models to identify high-risk populations. Animal models can teach us something about human bladder cancer and address the issue of the differentiation between papillary low-grade and invasive high-grade tumors. After the diagnosis of a bladder tumor, pathological risk stratification becomes important but there are weaknesses in the current grading systems. Molecular grading may provide a new, simple, and highly reproducible tool to determine bladder cancer prognosis. Based on our current knowledge, including gaps in that knowledge, education is the immediate top-priority action item. The promotion of smoking cessation is also a high priority action. The symptoms of bladder cancer, particularly hematuria, must be emphasized to both the medical and lay. Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent.",
keywords = "Bladder cancer, Cancer risk, Carcinogenesis",
author = "Zlotta, {Alexandre R.} and Cohen, {Samuel Monroe} and Colin Dinney and Michael Droller and {van der Kwast}, {Theo H.} and {van Rhijn}, {Bas W G} and Bernard Bochner and Gilad Ameil and Jewett, {Michael A S}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.urolonc.2009.10.011",
language = "English (US)",
volume = "28",
pages = "329--333",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - BCAN Think Tank session 1

T2 - Overview of risks for and causes of bladder cancer

AU - Zlotta, Alexandre R.

AU - Cohen, Samuel Monroe

AU - Dinney, Colin

AU - Droller, Michael

AU - van der Kwast, Theo H.

AU - van Rhijn, Bas W G

AU - Bochner, Bernard

AU - Ameil, Gilad

AU - Jewett, Michael A S

PY - 2010/5/1

Y1 - 2010/5/1

N2 - This article reviews the proceedings of the cause and risk session of the recently held BCAN Bladder Think Tank in 2009. Understanding associations between specific genetic changes and development of particular forms of bladder cancer, whether low-grade or more invasive forms, may justify screening programs for earlier detection. A fundamental epidemiological issue is causation. Associations are supported by high rates in industrialized regions and parallel associations with cigarette smoking. The evolution to molecular and integrative epidemiology incorporates molecular and cytogenetic markers in host and tumor tissue with classic epidemiology to develop risk assessment models to identify high-risk populations. Animal models can teach us something about human bladder cancer and address the issue of the differentiation between papillary low-grade and invasive high-grade tumors. After the diagnosis of a bladder tumor, pathological risk stratification becomes important but there are weaknesses in the current grading systems. Molecular grading may provide a new, simple, and highly reproducible tool to determine bladder cancer prognosis. Based on our current knowledge, including gaps in that knowledge, education is the immediate top-priority action item. The promotion of smoking cessation is also a high priority action. The symptoms of bladder cancer, particularly hematuria, must be emphasized to both the medical and lay. Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent.

AB - This article reviews the proceedings of the cause and risk session of the recently held BCAN Bladder Think Tank in 2009. Understanding associations between specific genetic changes and development of particular forms of bladder cancer, whether low-grade or more invasive forms, may justify screening programs for earlier detection. A fundamental epidemiological issue is causation. Associations are supported by high rates in industrialized regions and parallel associations with cigarette smoking. The evolution to molecular and integrative epidemiology incorporates molecular and cytogenetic markers in host and tumor tissue with classic epidemiology to develop risk assessment models to identify high-risk populations. Animal models can teach us something about human bladder cancer and address the issue of the differentiation between papillary low-grade and invasive high-grade tumors. After the diagnosis of a bladder tumor, pathological risk stratification becomes important but there are weaknesses in the current grading systems. Molecular grading may provide a new, simple, and highly reproducible tool to determine bladder cancer prognosis. Based on our current knowledge, including gaps in that knowledge, education is the immediate top-priority action item. The promotion of smoking cessation is also a high priority action. The symptoms of bladder cancer, particularly hematuria, must be emphasized to both the medical and lay. Given the costs associated with the treatment and surveillance of bladder cancer, a comprehensive program supported by governmental funding sources to identify the risks associated with bladder cancer development would seem prudent.

KW - Bladder cancer

KW - Cancer risk

KW - Carcinogenesis

UR - http://www.scopus.com/inward/record.url?scp=77951660145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951660145&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.10.011

DO - 10.1016/j.urolonc.2009.10.011

M3 - Review article

VL - 28

SP - 329

EP - 333

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -